

## Publications

### Original work in peer-reviewed journals

- (1) **Schmidt E**, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Nast A, Orzechowski HD, Pfeiffer C, Schuster V, Sitaru C, Zidane M, Zillikens D, Worm M. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. *J Dtsch Dermatol Ges*, 2020;18:516-26. IF 3.9
- (2) **Schmidt E**, Steinhagen K, Rupp J. Heavy exposure of children aged 9 to 12 years with SARS-CoV-2 did not lead to infection. *J Ped Infect Dis Soc* 2020, in press. IF 2.2.
- (3) Hijnen D, Marzano AV, Eyerich K, GeurtsvanKessel C, Giménez-Arnau AM, Joly P, Vestergaard C, Sticherling M, **Schmidt E**. SARS-CoV-2 transmission from presymptomatic meeting attendee, Germany. *Emerg Infect Dis*. 2020, 11: 26. IF 6.3
- (4) Joly P, Horwath B, Patsatsi K, Uzun S; Bech R, Beissert S, Bergman R, Bernard P, Borradori L, Caproni M, Caux F, Cianchini G, Daneshpazhooh M, Dipankar D, Dmochowski M, Drenovska K, Ehrchen J, Feliciani C, Goebeler M, Groves R, Guenther C, Hofmann S, Ioannides D, Kowalewski C, Ludwig R, Lim YL, Marinovic B, Marzano AV, Mascaro JM, Mimouni D, Murrell D, Pincelli C, Prost Squarcioni C, Sardy M, Setterfield J, Sprecher E, Vassileva S, Wozniak K, Yayli S, Zambruno G, Zillikens D, Hertl M, **Schmidt E**. Updated S2k guideline on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). *J Eur Acad Dermatol Venereol*, in press. IF 5.1
- (5) Holtsche MM, Goletz S, Georg A, van Beek N, Hübner F, Pigors M, Zillikens D, **Schmidt E**. Serological characterization of anti-p200 pemphigoid: epitope spreading as a common phenomenon. *J Am Acad Dermatol*. 2020, in press. IF 8.3
- (6) Hübner F, König IR, Holtsche MM, Zillikens D, Linder R **Schmidt E**. Prevalence and age distribution of pemphigus and pemphigoid diseases among pediatric patients in Germany. *J Eur Acad Dermatol Venereol*, in press. IF 5.1
- (7) van Beek N, Krüger S, Fuhrmann T; Lemcke S, Goletz S, Probst C, Komorowski L, Di Zenzo G, Dmochowski M, Drenovska K, Horn M, Jedlickova H, Kowalewski C, Medenica L, Murrell D, Patsatsi A, Geller S, Uzun S, Vassileva S, Zhu X, Fechner K, Zillikens D, Stöcker W, **Schmidt E\***; Rentzsch K\*. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. *J Am Acad Dermatol*, in press. \*equal contribution, IF 6.9
- (8) Kasprick A, Hofrichter M, Smith B, Ward P, Gupta Y, Bieber K, Shock A, Ludwig R\*, **Schmidt E\***. Anti-neonatal Fc receptor (FcRn) antibody treatment ameliorates experimental epidermolysis bullosa acquisita in mice. *Br J Pharmacol*, in press. \*equal contribution, IF 6.6
- (9) Holtsche M, Hammers M, Chakievska L, Ludwig R, Thaci D, Zillikens D, **Schmidt E**. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. *J Dtsch Dermatol Ges*, in press, IF 3.9
- (10) Boch K, Ludwig R, Zillikens D, **Schmidt E**. Penile mucous membrane pemphigoid *J Dtsch Dermatol Ges*, in press, IF 3.9
- (11) Kasperkiewicz M, **Schmidt E**, Fairley JA, Joly P, Payne AS, Yale ML, Zillikens D, Woodley DT. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. *J Eur Acad Dermatol Venereol* 2020, in press. IF 6.9
- (12) Ständer S, **Schmidt E**, Zillikens D, Ludwig R, Kridin K. More severe erosive phenotype despite lower circulating autoantibody levels in dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: A retrospective cohort study. *Am J Clin Dermatology* 2020, in press. IF 5.1
- (13) Boch K, Zillikens D, Langan EA, **Schmidt E**, Ludwig RJ. Low prevalence of late-onset neutropenia following rituximab treatment in patients with pemphigus. *J Am Acad Dermatol*. 2020, in press. IF 8.3

- (14) Rongisch R, **Schmidt E**, Deresz N, Deresz K, Schöfer H, Just-Nübling G, Schäkel K, Jakob T, Maurer M, Sticherling M, Sunderkötter C, Babilas P, Spornraft-Ragaller P, Traidl-Hoffmann C, Gläser R, Hartmann K, Kolb-Mäurer A, Wenzel J, Biedermann T, Homey B, Pfützner W, Weid F, Fischer M, Linder R, von Stebut E. Travel-associated infectious skin diseases. *J Dtsch Dermatol Ges*, in press, IF 3.9
- (15) Khilchenko S, Boch K, van Beek N, Vorobyev A, Zillikens D, **Schmidt E**, Ludwig RJ. Alterations of total serum immunoglobulin concentrations in pemphigus and pemphigoid: Selected IgG2 deficiency in bullous pemphigoid. *Front Med*, in press. IF 3.9
- (16) Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Reich K, Mauch C, **Schmidt E**, Schön M, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M. COVID-19 and implications for dermatological and allergological diseases. *J Dtsch Dermatol Ges*, in press, IF 3.9
- (17) Burmester I, Flaszinkel S, Thies CS, Kasprick A, Kamaguchi M, Bumiller-Bini V, Emtenani S, Feldmann N, Kridin K, **Schmidt E**, van Beek N, Zillikens D, Hammers CM, Hundt J, Ludwig R. Identification of novel therapeutic targets for blocking acantholysis in pemphigus. *Br J Dermatol*, in press. IF 7.7
- (18) Shimanovich I, Baumann T, **Schmidt E**, Zillikens D, Hammers C. Long-term outcomes of rituximab therapy in pemphigus. *J Eur Acad Dermatol Venereol*, in press. IF 5.1
- (19) Ernst N, Friedrich M, Bieber K, Kasperkiewicz M, Gross N, Sadik CD, Zillikens D, **Schmidt E**, Ludwig R, Hartmann K. Expression of PD-1 and Tim-3 is increased in bullous pemphigoid and pemphigus vulgaris. *J Eur Acad Dermatol Venereol*, in press. IF 5.1
- (20) Tarnowietzki E, Peters T, Kraus L, **Schmidt E**, Scharfetter-Kochanek K. Remission of anti-laminin 332 mucous membrane pemphigoid associated with non-small cell lung cancer after therapy with intravenous immunoglobulin. *Acta Dermatol Venereol (Stockh.)*, in press. IF 4.0
- (21) Ali OH, Bomze D, Ring S, Berner F, Fässler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A, Cozzio A, Bernhard M, Jochum W, **Schmidt E**, Zillikens D, Sadik CD, Flatz L. BP180-specific IgG is associated with overall survival, therapy response and cutaneous adverse events in lung cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol* 2020, 82: 854-61. IF 7.1
- (22) Ständer S, Färber B, Radeke S, **Schmidt E**, Zillikens D, Ludwig R. Assessment of the healthcare costs for pemphigus and bullous pemphigoid patients in an academic center in Germany. *Br J Dermatol*, 2020, 182: 1296-96. IF 6.1
- (23) Egu DT, Sigmund AM, **Schmidt E**, Spindler V, Walter E, Waschke J. p38MAPK inhibition is not effective to prevent autoantibody-induced mucosal blistering in pemphigus. *Br J Dermatol* 2020, 182: 987-94. IF 6.1
- (24) Murrell D, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne A, Daneshpazhooch M, Eming R, Jonkman M, Mimouni D, Borradori L, Kim SC, Yamagami J, Lehman J, Saleh MA, Culton D, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman-Karakas A, Bernard P, Korman N, Caux F, Drenovska K, Prost-Squarcioni C, Vassileva S, Feldman R, Cardones A, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, **Schmidt E**, Aoki V, Grando S, Shimizu H, Baum S, Cianchini G, Feliciani C, Iranzo P, Mascar J, Kowalewski C, Hall R, Groves R, Harman K, Marinkovich P, Maverakis E, Werth V. Diagnosis and management of pemphigus: Recommendations by an international panel of experts. *J Am Acad Dermatol* 2020, 82:575–585. IF 7.1
- (25) Chakievska L, Holtsche MM, Künstner A, Goletz S, Petersen BS, Thaci D, Ibrahim SM, Ludwig RJ, Franke A, Sadik CD, Zillikens D, Hölscher C, Busch H, **Schmidt E**. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. *J Autoimmun* 2019; 96: 104-12. IF 7.6
- (26) Goletz S, Probst C, Komorowski L, Schlumberger W, Fechner K, van Beek N, Holtsche MM, Recke A, Yancey KB, Hashimoto T, Antonicelli F, Di Zenzo G, Zillikens D, Stöcker W, **Schmidt E**. Sensitive and specific assay for the serological diagnosis of anti-laminin 332 mucous membrane pemphigoid. *Br J Dermatol* 2019, 180: 149-56. IF 7.0
- (27) Lau I, Goletz S, Holtsche MM, Zillikens D, Fechner K, **Schmidt E**. Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by

- indirect immunofluorescence microscopy on human salt-split skin. *J Am Acad Dermatol* 2019, 81: 1195-97. IF 8.3
- (28) Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, **Schmidt E**, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. *JCI Insight* 2019, 8:4. IF 6.2
- (29) Oliveira LC, Kretschmar GC, Moraes Santos AC, Camargo CM, Nisihara RM, Della Justina Farias T, Franke A, Wittig M, **Schmidt E**, Busch H, Petzl-Erler ML, Winter Boldt AB. Complement Receptor 1 (CR1, CD35) polymorphisms and soluble CR1: a proposed anti-inflammatory role to quench the fire of "fogo selvagem" pemphigus foliaceus. *Front Immunol*, 2019, 10: 2585. IF 5.1
- (30) Russlies J, Fähnrich A, Witte M, Yin J, Benoit S, Gläser S, Günther C, Eming R, Erdmann J, Gola D, Gupta Y, Holtsche MM, Kern JS, König I, Kiritsi D, Lieb W, Sadik C, Sárdy M, Schauer F, van Beek N, Weidinger A, Worm M, Zillikens D, **Schmidt E**, Busch H, Ibrahim S, Hirose M. Polymorphisms in the mitochondrial genome are associated with bullous pemphigoid in Germans. *Front Immunol* 2019, 10: 2200. IF 5.1
- (31) Mahmoudi H, Toosi R, Kamyab K, Zillikens D, **Schmidt E**, Daneshpazhooh M. Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LAD-1). *J Dtsch Dermatol Ges* 2019, 17: 933-36. IF 3.7
- (32) Wald A, **Schmidt E**, Toberer F, Enk AH, Hoffmann J. Overlap of bullous, anti-laminin 332 and p200 pemphigoid with concomitant anti-contactin 1-positive inflammatory polyneuropathy treated with intravenous immunoglobulins as a manifestation of epitope spreading. *JAMA Dermatol* 2019, 155: 631-33. IF 7.7
- (33) Gutjahr A, Heck F, Emtenani S, Hammers AK, Hundt J, Muck P, Siegel DL, **Schmidt E**, Stanley JR, Zillikens D, Hammers CM. Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium. *Br J Dermatol* 2019, 181: 593-94. IF 7.0
- (34) Shi C, Meijer J, Guoc J, Azzopardia G, Diercks G, **Schmidt E**, Zillikens D, Jonkman MF, Petkova N. Detection of *u*-serrated patterns in direct immunofluorescence images of autoimmune bullous diseases by inhibition-augmented COSFIRE filters. *Int J Med Inform* 2019, 122: 122-27. IF 3.0
- (35) Hebert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, **Schmidt E**, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French. Large international validation of ABSIS and PDAI pemphigus severity scores. *J Invest Dermatol* 2019, 139: 31-37. IF 7.1
- (36) Emtenani S, Yuan H, Lin C, Pan M, Hundt JE, **Schmidt E**, Komorowski L, Stanley JR, Hammers CM. Normal human skin is superior to monkey esophagus substrate for detection of circulating BP180-NC16A-specific immunoglobulin G antibodies in bullous pemphigoid. *Br J Dermatol* 2019, 180: 1099-1106. IF 7.0
- (37) Daneshpazhooh M, Mahmoudi H, Toosi R, Tavakolpour S, **Schmidt E**, Zillikens D. Post-orf epidermolysis bullosa acquisita. *J Eur Acad Dermatol Venereol* 2019, 33:118-19. IF 5.2
- (38) Ellenbogen E, Geller S, Azrielant S, Zeeli T, Goldberg I, **Schmidt E**, Zillikens D, Sherman S, Mercer S, Didkovsky E, Hodak E, Sprecher E. Grover disease and bullous pemphigoid: a clinicopathologic study of six cases. *Clin Exp Dermatol* 2019, 44: 524-27. IF 2.0
- (39) Syring FM, Zillikens D, **Schmidt E**, Kasperkiewicz M. Anti-Laminin 332 Schleimhautpemphigoid mit irreversiblen okulären und tracheobronchialen Befall. *Hautarzt* 2019, 70: 367-70. IF 0.7
- (40) Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze F, Heppe EN, Ludwig R, Zillikens D, König IR, Köhl J, **Schmidt E**. Tissue destruction in bullous

- pemphigoid can be complement-independent and may be mitigated by C5aR2. *Front Immunol* 2018, 9: 488. IF 4.7
- (41) Holtsche MM, Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S, English J, Sticherling M, Chapman Levell ANJ, Groves R, Williams HV, König IR, **Schmidt E**. Prospective study in bullous pemphigoid: Association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. *Br J Dermatol* 2018, 179: 918-24. IF 6.7
  - (42) Hofrichter M, Dworschak J, Langenhan J, Weiß F, Komorowski L, Zillikens D, Stöcker W, Probst C, **Schmidt E**, Goletz S\*. Immunoabsorption of anti-desmoglein 3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice. *Front Immunol* 2018, 9: 1935. \*equal contribution, IF 4.7
  - (43) Spindler V\*, Eming R\*, **Schmidt E**\*, Amagai M, Grando S, Jonkman MF, Kowalczy AP, Müller EJ, Payne AS, Pincelli C, Sinha AA, Sprecher E, Zillikens D\*, Hertl M\*, Waschke J\*. Mechanisms causing loss of keratinocyte cohesion in pemphigus. *J Invest Dermatol* 2018, 138: 32-37. \*equal contribution, IF 6.3
  - (44) Recke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, Amoli MM, Benoit S, El-Chennawy F, Eldarouti M, Eming R, Gläser R, Günther C, Hadaschik E, Homey B, Lieb W, Peitsch WK, Pföhler C, Robati RM, Saeedi M, Sárdy M, Sticherling M, Uzun S, Worm M, Zillikens D, Ibrahim S, Vidarsson G, **Schmidt E**, and the German AIBD Genetic Study Group. The p.Arg435His variation of IgG3 with high affinity to FcRn is associated with susceptibility for pemphigus vulgaris – analysis of four different ethnic cohorts. *Front Immunol* 2018, 9: 1788. IF 4.7
  - (45) Hübner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hübner J, Sufke S, Muck P, Zillikens D, **Schmidt E**. Adjuvant treatment of severe/ refractory bullous pemphigoid with protein A immunoabsorption leads to rapid disease control and decrease of anti-BP180 autoantibody levels. *J Dtsch Dermatol Ges* 2018, 16: 1109-18. IF 3.9
  - (46) Kasperkiewicz M, Mook SC, Knuth-Rehr D, Vorobyev A, Ludwig R, Zillikens D, Muck P, **Schmidt E**. IgE-selective immunoabsorption for severe atopic dermatitis. *Front Med* 2018, 5: 27. IF 3.1
  - (47) Hügel R, Lang A, Lhotta K, Elsässer W, Gächter W, Messmer EM, **Schmidt E**. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement - adjuvant treatment with immunoabsorption and rituximab. *J Dtsch Dermatol Ges* 2018, 16: 897-900. IF 3.9
  - (48) Haeberle S, Wei X, Bieber K, Goletz S, Ludwig RJ, **Schmidt E**, Enk AH, Hadaschik EN. Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. *J Allergy Clin Immunol* 2018, 142: 1831-42. IF 14.1
  - (49) Meijer JM, Atefi I, Diercks G, Vorobyev A, Zuiderveen J, Meijer JH, Pas HH, Zillikens D, **Schmidt E**, Jonkman M. Serration pattern analysis for differentiating epidermolysis bullosa acquisita from pemphigoid variants. *J Am Acad Dermatol* 2018, 78: 754-759. IF 7.1
  - (50) Prost-Squarcioni C, Caux F, **Schmidt E**, Jonkman MF, Vassileva S, Kim SC, Iranzo P, Daneshpazhoo M, Terra J, Bauer J, Fairley J, Hall R, Hertl M, Lehman JS, Marinovic B, Patsatsi A, Zillikens D, Werth V, Woodley DT, Murrell DF. International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. *Br J Dermatol* 2018, 179: 30-14. IF 6.7
  - (51) Hübner F, Setterfield J, Recke A, Zillikens D, **Schmidt E**, Dart J, Ibrahim S. HLA alleles in British Caucasians with mucous membrane pemphigoid. *Eye* 2018, 32: 1540-41. IF 2.4
  - (52) Menzinger S, Kaya G, **Schmidt E**, Fontao L, Laffitte E. Biological and clinical response to omalizumab in a patient with bullous pemphigoid. *Acta Derm Venereol* 2018, 98: 284-86. IF 3.5
  - (53) Kasprick A, Holtsche M, Kauderer C, **Schmidt E**, Petersen F, Panicker S, Ludwig R. The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies. *J Invest Dermatol* 2018, 138: 458-61. IF 6.3
  - (54) Tukaj S, Bieber K, Witte M, Ghorbanalipour S, **Schmidt E**, Zillikens D, Ludwig R, Kasperkiewicz M. Calcitriol treatment ameliorates inflammation and blistering in mouse models of epidermolysis bullosa acquisita. *J Invest Dermatol* 2018, 138: 301-309. IF 6.3

- (55) Samavedam U, Mitschker N, Kasprick A, Bieber K, **Schmidt E**, Laskay T, Recke A, Vidarsson G, Schulze FS, Armbrust M, Schulze Dieckhoff K, Pas HH, Jonkman M, Kalies K, Zillikens D, Gupta Y, Ibrahim S, Ludwig R. Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in experimental epidermolysis bullosa acquisita. *Front Immunol* 2018, 9: 249. IF 4.7
- (56) Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, **Schmidt E**, Harman K, Walton S, Chapman A, Williams HC; U.K.Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. *Br J Dermatol* 2018, 178: 415-23. IF 6.7
- (57) Jankásková J, Horváth ON, Varga R, Arenberger P, **Schmidt E**, Ruzicka T, Sárdy M. Increased sensitivity along with high specificity of indirect immunofluorescence detecting IgG subclasses for diagnosis of bullous pemphigoid. *Clin Exp Dermatol* 2018, 43: 248-53. IF 1.7
- (58) Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, **Schmidt E**, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T. Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy: Data from a nationwide German registry (GRAID2). *Z Rheumatol* 2018, 77: 28-39. IF 0.9
- (59) **Schmidt E**. Rituximab as first line therapy of pemphigus (translational comment). *Lancet* 2017, 389: 1956-58. IF 53.2
- (60) Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C, Zillikens D, Köhl J, Goletz S, **Schmidt E**. Experimental laminin 332 mucous membrane pemphigoid reflects clinical and immunopathological characteristics of the human disease and critically involves C5aR1. *J Invest Dermatol* 2017, 137: 1709-18. IF 6.4
- (61) van Beek N, Lütmann N, Hübner F, Recke A, Karl I, Schulze FS, Zillikens D, **Schmidt E**. Serum levels of IgE autoantibodies against BP180: correlation with disease activity in patients with bullous pemphigoid but not with the type of clinical presentation. *JAMA Dermatol* 2017, 153: 30-38. IF 8.1
- (62) van Beek N, Dährnich C, Johannsen N, Lemcke S, Goletz S, Hübner F, Di Zenzo G, Dmochowski M, Drenovska K, Geller S, Horn M, Kowalewski C, Medenica L, Murrell DF, Patsatsi A, Uzun S, Vassileva S, Zillikens D, Schlumberger W, **Schmidt E**. Prospective studies on the routine use of a novel multivariant ELISA for the diagnosis of autoimmune bullous diseases. *J Am Acad Dermatol* 2017, 76: 889-894. IF 6.9
- (63) Sticherling M, Franke A, Aberer E, Gläser R, Hertl M, Pfeiffer C, Rzany B, Schneider S, Shimanovich I, Werfel T, Wilczek A, Zillikens D, **Schmidt E**. An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. *Br J Dermatol* 2017; 177: 1299-1305. IF 6.1
- (64) Sadik C, Pas HH, Bohlmann MK, Mousavi S, Benoit S, Sárdy M, Terra JB, Lima AL, Hammers CM, van Beek N, Bangert C, Zillikens D, **Schmidt E**. Value of BIOCHIP technology in the diagnosis of pemphigoid gestationis. *Acta Dermatol Venereol (Stockh.)* 2017, 97: 128-30. IF 3.1
- (65) Mindorf S, Dettmann I, Krüger S, Fuhrmann T, Rentzsch K, Ingolf K, Probst C, Komorowski L, Fechner K, van Beek N, Lemcke S, Sárdy M, Bangert C, Benoit S, Hashimoto T, Zillikens D, Pas H, Jonkman M, Stöcker W, **Schmidt E**. Routine detection of serum anti-desmocollin autoantibodies is only useful in patients with atypical pemphigus. *Exp Dermatol* 2017, 26: 1267-70. IF 2.6
- (66) **Schmidt E**, Spindler V, Eming R, Amagai M, Antonicelli F, Baines JF, Belheouane M, Bernard P, Borradori L, Caproni M, Di Zenzo G, Grando S, Harman K, Jonkman MF, Koga H, Ludwig R, Kowalczyk AP, Müller EJ, Nishie W, Pas H, Payne A, Sadik C, Seppänen A, Setterfield J, Shimizu H, Sinha AA, Sprecher E, Sticherling M, Ujii H, Zillikens D, Hertl M, Waschke J. Meeting report of the *Pathogenesis of Pemphigus and Pemphigoid Meeting* in Munich, September 2016. *J Invest Dermatol* 2017, 137: 1199-1203. IF 6.4

- (67) **Schmidt E**, Benoit S, Kampik D, Hille K, Geerling G. Tibia-keratoprosthesis: Reversing blindness in mucous membrane pemphigoid. *J Dtsch Dermatol Ges* 2017, 15: 1024-26. IF 2.7
- (68) Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, **Schmidt E**, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid – a pragmatic non-inferiority randomised controlled trial. *Lancet* 2017, 389: 1630-38. IF 53.2
- (69) Williams HC, Chalmers JR, Nunn AJ, **Schmidt E**. BLISTER tests the strategy of starting pemphigoid treatment with doxycycline (reply). *Lancet* 2017, 390: 135-36. IF 53.2
- (70) Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, **Schmidt E**, Godec TR, Nunn AJ, Williams HC. A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. *Health Technol Asses* 2017, 21: 1-90. IF 4.2
- (71) Miodovnik M, Künstner A, Langan E, Zillikens D, Gläser R, Sprecher E, Baines J\*, **Schmidt E\***, Ibrahim S\*. A distinct cutaneous microbiota profile in autoimmune bullous diseases patients. *Exp Dermatol* 2017, 26: 1221-27. IF 2.6. \* equal contribution
- (72) Sezin T, Krajewski M, Wutkowski A, Mousavi S, Bieber K, Ludwig R, Dahlke M, Rades D, Schulze FS, **Schmidt E**, Kalies K, Gupta Y, Schilf P, Ibrahim S, König P, Schwudke D, Zillikens D, Sadik C. The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita. *J Invest Dermatol* 2017, 137: 1104-13. IF 6.4
- (73) Bieber K, Sun S, Witte M, Kasprick A, Beltsiou F, Behnen M, Laskay T, Schulze FS, Pipi E, Reichhelm N, Pagel R, Zillikens D, **Schmidt E**, Sparwasser T, Kalies K, Ludwig R. Regulatory T cells suppress inflammation and blistering in pemphigoid diseases. *Front Immunol* 2017, 8: 1628. IF 5.5
- (74) Bieber K, Ernst AL, Tukaj S, Holtsche M, **Schmidt E**, Zillikens D, Ludwig R, Kasperkiewicz M. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. *Exp Dermatol* 2017, 26: 1248-52. IF 2.6
- (75) Sadik C, Bischof J, van Beek N, Dieterich A, Benoit S, Sardy M, Worm M, Meller S, Gläser R, Zillikens D, Homey B, Setterfield J, Minassian D, **Schmidt E**, Dart J, Ibrahim S. Genome-wide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid. *Exp Dermatol* 2017, 26: 1214-20. IF 2.6
- (76) Maier L, Udvardi A, Hertl M, Eming R, **Schmidt E**, Zillikens D, Volc-Platzer B. Paraneoplastic pemphigus with anti-BP180 autoantibodies and Castleman's disease. *Br J Dermatol* 2017, 176: 824-26. IF 6.1
- (77) Walter E, Vielmuth F, Rotkopf L, Sardy M, Horváth ON, Goebeler M, **Schmidt E**, Eming R, Hertl M, Spindler V, Waschke J. Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus. *Sci Rep* 2017, 7: 3579. IF 4.1
- (78) Bağcı IS, Horváth ON, **Schmidt E**, Ruzicka T, Sárdy M. Diagnostic Value of linear fluorescence along the basement membrane of sweat gland ducts in bullous pemphigoid. *Acta Derm Venereol* 2017, 97: 622-26. IF 3.1
- (79) Reichel A, Benoit S, Giner T, **Schmidt E**, Goebeler M, Stoevesandt J. Anti-desmoglein 1 IgG/IgA pemphigus associated with thymoma. *J Dtsch Dermatol Ges* 2017, 15: 1147-49. IF 2.7
- (80) Mergler R, Kerstan A, **Schmidt E**, Goebeler M, Benoit S. Atypical clinical and serological manifestation of pemphigus vegetans: A case report and review of the literature. *Case Rep Dermatol* 2017, 9: 121-30. IF 0.25
- (81) Patsatsi A, Parthena M, Katafygiotis S, Sotiriadis D, **Schmidt E**, Lambropoulos A. Chronic bullous disease of childhood with IgG reactivity to p200 antigen. *Int J Dermatol* 2017, 56: 773-75. IF 1.5
- (82) Goyal N, Rao R, Shenoi SD, Pai S, Kumar P, Bhogal BS, **Schmidt E**, Zillikens D. Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal

- autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin. *Indian J Dermatol Venereol Leprol* 2017, 83: 550-55. IF 2.2
- (83) Hirose M, Kasprick A, Beltisou F, Schulze-Dieckhoff K, Schulze FS, Samavedam U, Hundt J, Pas H, Jonkman M, **Schmidt E**, Kalies K, Zillikens D, Ludwig R, Bieber K. Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment. *Mol Med* 2016, 22: 918-26. IF 3.5
- (84) Hübner F, Recke A, Zillikens D, Linder R, **Schmidt E**. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. *J Invest Dermatol* 2016, 136: 2495-98. IF 6.3
- (85) Recke A, Oei A, Hübner F, Fechner K, Graf J, Hagenah J, May C, Voitalla D, Salmen A, Zillikens D, Gold R, Schlumberger W, **Schmidt E**. Parkinson's disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. *Br J Dermatol* 2016, 175: 407-09. IF 4.7
- (86) **Schmidt E**. Increasing the diagnostic sensitivity for mucous membrane pemphigoid by detection of salivary autoantibodies (commentary). *Br J Dermatol* 2016, 174: 956-57. IF 4.7
- (87) Mersmann M, Dworschak J, Ebermann K, Komorowski L, Schlumberger W, Stöcker W, Zillikens D, Probst C, **Schmidt E**. Immunoabsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. *Arch Dermatol Res* 2016, 308: 31-38. IF 2.3
- (88) Lemcke S, Sokolowski S, Rieckhoff N, Buschtez M, Kaffka C, Winter-Keil A, Schaller C, Rottmann N, Sadik C, Stöcker W, Zillikens D, **Schmidt E**. Automation of direct immunofluorescence microscopy for skin biopsies to improve accuracy and efficiency in routine diagnostics. *J Cutan Pathol* 2016, 43: 227-35. IF 1.4
- (89) Commin MH, **Schmidt E**, Duvert-Lehembre S, Lasek A, Morice C, Estival JL, Debarbieux S, Rigal E, Pauwels C, De Quatrebarbes J, Roussel A, Goujon E, Stoebner PE, Jouen F, Joly P. Clinical and immunological features and outcome of anti-p200 pemphigoid. *Br J Dermatol* 2016, 175: 776-81. IF 4.7
- (90) Meijer JM, Diercks G, **Schmidt E**, Pas H, Jonkman MF. Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. *JAMA Dermatol* 2016, 152:897-904. IF 5.8
- (91) Ahmed R, Carrozzo M, Caux F, Cirillo N, Dmochowski M, Alonso A, Gniadecki R, Hertl M, López-Zabalza M, Lotti R, Pincelli C, Pittelkow M, **Schmidt E**, Sinha A, Sprecher E, Grando S. Monopathogenic versus multipathogenic explanations of pemphigus pathophysiology. *Exp Dermatol* 2016, 72: 168-74. IF 3.8
- (92) Geller S, Gat A, Zeeli T, **Schmidt E**, Ishii N, Hashimoto T, Zillikens D, Sprecher E. A refractory, cutaneous, subepidermal bullous disease. *Clin Exp Dermatol*. 2016, 41: 573-75. IF 1.3
- (93) Horváth O, Varga R, Kaneda M, **Schmidt E**, Ruzicka T, Sárdy M. Diagnostic performance of the MESACUP Anti-Skin Profile ELISA. *Eur J Dermatol* 2016, 26: 56-63. IF 2.0
- (94) Griss J, Stingl G, **Schmidt E**, Bangert C. A rare bullous variant of dermatitis herpetiformis. *Br J Dermatol* 2016, 174: 231-32. IF 4.7
- (95) Goyal N, Rao R, Balachandran C, Pai S, Bhogal BS, **Schmidt E**, Zillikens D. Childhood epidermolysis bullosa acquisita: confirmation of diagnosis by skin deficient in type VII collagen, enzyme-linked immunosorbent assay, and immunoblotting. *Indian J Dermatol* 2016, 61: 329-32. IF 1.9
- (96) Akbarzadeh R, Yu X, Vogl T, Ludwig R, **Schmidt E**, Zillikens D, Petersen F. Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid. *J Dermatol Sci* 2016, 81: 165-72. IF 3.7
- (97) Galli-Novak E, Mook SC, Büning J, **Schmidt E**, Zillikens D, Thaci D, Ludwig R. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. *J Eur Acad Dermatol Venereol* 2016, 30: 191-192. IF 3.5

- (98) Schulze F, Neumann K, Recke A, Zillikens D, Linder R, **Schmidt E**. Malignancies in pemphigus and pemphigoid diseases. *J Invest Dermatol* 2015, 135: 1445-47. IF 6.9
- (99) Sadeghi H, Lockmann A, Hund AC, Samavedam U, Pipi E, Vafia K, Hauenschield E, Kalies K, Pas HH, Jonkman MF, Iwata H, Recke A, Schön M, Zillikens D, **Schmidt E\***, Ludwig R\*. Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules. *J Immunol* 2015, 194: 3656-63. IF 5.4. \* equal contribution.
- (100) **Schmidt E**, Goebeler M, Hertl M, Sárdy M, Sitaru C, Eming R, Hofmann S, Hunzelmann N, Kern JS, Kramer H, Orzechowski HD, Pfeiffer C, Schuster V, Sporbeck B, Sticherling M, Worm M, Zillikens D, Nast A. S2k Guidelines for diagnosis of pemphigus vulgaris / foliaceus and bullous pemphigoid. *J Dtsch Dermatol Ges* 2015, 13: 713-727. IF 2.5
- (101) Recke A, Vidarsson G, Ludwig R, Freitag M, Möller S, Vonthein R, Schellenberger J, Haase O, Görg S, Nebel A, Flachsbarf F, Schreiber S, Lieb W, Gläser R, Benoit S, Sárdy M, Eming R, Hertl M, Zillikens D, König I, **Schmidt E**, Ibrahim S, and the German AIBD Genetic Study Group. Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseases. *J Autoimmun* 2015, 61: 36-44. IF 7.0
- (102) Eming R, Sticherling M, Hofmann S, Hunzelmann N, Kern JS, Kramer H, Pfeiffer C, Schuster V, Zillikens D, Goebeler M, Hertl M, Nast A, Orzechowski HD, Sárdy M, **Schmidt E**, Sitaru C, Sporbeck B, Worm M. S2k Guidelines for the treatment of pemphigus vulgaris / foliaceus and bullous pemphigoid. *J Dtsch Dermatol Ges* 2015, 13: 833-845. IF 2.5
- (103) Sadeghi H, Gupta Y, Möller S, Samavedam UK, Behnen M, Kasprick A, Bieber K, Müller S, Kalies k, de Castro Marques A, Recke A, **Schmidt E**, Zillikens D, Laskay T, Mariani J, Ibrahim S, Ludwig R. The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita. *J Pathol* 2015, 237: 111-122. IF 6.8
- (104) Hirose M, Schilf P, Benoit S, Eming R, Gläser R, Homey B, Kunz M, Nebel A, Peitsch WK, Pföhler C, Sárdy M, Schreiber S, Zillikens D, **Schmidt E**, Ibrahim SM; German AIBD Genetic Study Group. Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population. *Exp Dermatol* 2015, 24: 715-7. IF 3.7
- (105) Prüllmann W, Prüllmann J, Koga H, Recke A, Iwata H, Juhl D, Görg S, Henschler R, Hashimoto T, **Schmidt E**, Zillikens D, Ibrahim S, Ludwig R. Prevalence of pemphigus and pemphigoid autoantibodies in the general population. *Orphanet J Rare Dis* 2015, 10:63. IF 4.0
- (106) Kunz M, König I, Schillert A, Kruppa J, Ziegler A, Grallert H, Müller-Nurasyid M, Lieb W, Franke A, Ranki A, Panelius J, Koskenmies S, Hasan T, Kere J, Rönn A, Simon JC, **Schmidt E**, Wenzel J, Tüting T, Landsberg J, Zeller T, Blankenberg S, Gläser R, Patsinakidis N, Kuhn A, Ibrahim S. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. *Exp Dermatol* 2015, 24: 510-515. IF 3.7
- (107) Haase O, Alnebari R, Eldarouti MA, Abd El Hady M, Dorgham D, El-Nabarawy E, El Din Mahmoud SB, Mosaad El Sayed H, Darwish M, Abbas F, Salah S, Mosaad Y, El Chennawy F, Al Mongy S, Abdelaziz AM, Abd El Gaber S, Hertl M, Eming R, Recke A, Möller S, **Schmidt E**, Zillikens D, Ibrahim S. Association with HLA-DRB1 in Egyptian and German pemphigus vulgaris patients. *Tissue Antigens* 2015, 85: 283-86. IF 2.4
- (108) Agrawal P, George R, Thomas M, Has C, Pas H, **Schmidt E**, Leverkus M. A childhood subepidermal autoimmune bullous disease resembling mechanobullous epidermolysis bullosa acquisita. *Br J Dermatol* 2015, 173:227-234. IF 4.3
- (109) van Beek N, Patsatsi A, Gupta Y, Möller S, Freitag M, Lemcke S, Recke A, Zillikens D, **Schmidt E**, Ibrahim S. A family with atypical Hailey Hailey disease- is there more to the underlying genetics than ATP2C1? *Plos One* 2015, 10: e121253. IF 3.7
- (110) Vorobyev A, Ujiie H, Recke A, Buijsrogge J, Jonkman M, Iwata H, Hashimoto T, Kim SC, Kim JH, Groves R, Samavedam U, Gupta Y, **Schmidt E**, Zillikens D, Shimizu H, Ludwig R.



- Autoantibodies to multiple epitopes on the non-collagenous-1 domain of type VII collagen induce blisters. *J Invest Dermatol* 2015, 135: 1565-73. IF 7.2
- (111) Langenhan J, Mersmann M, Dworschak J, **Schmidt E**, Probst C, Stöcker W. Track Z: Novel developments in the diagnosis and treatment of autoimmune blistering diseases. *Biomed Tech (Berl)* 2015; 60: s407-25. IF 1.2
- (112) Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Köhl J, Goletz S, Zillikens D, Ludwig R, **Schmidt E**. Fc $\gamma$ RIII and Fc $\gamma$ RIV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. *Am J Pathol* 2014, 184: 2185-96. IF 4.8
- (113) Kasperkiewicz M, Sufke S, **Schmidt E**, Zillikens D. IgE-specific immunoabsorption for treatment of recalcitrant atopic dermatitis. *JAMA Dermatology* 2014, 150: 1350-51. IF 4.8
- (114) Miyamoto J, Bockle BC, Zillikens D, **Schmidt E**, Schmuth M. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. *JAMA Dermatology* 2014, 150: 1120-1122. IF 4.8
- (115) Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D, **Schmidt E**. Treatment of bullous pemphigoid with adjuvant immunoabsorption: a case series. *J Am Acad Dermatol* 2014, 71: 2018-20. IF 5.0
- (116) Van Beek N, Dohse A, Riechert F, Krull V, Recke A, Zillikens D, **Schmidt E**. Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals, and blood donors prospectively recruited. *Br J Dermatol* 2014, 170: 943-7. IF 4.1
- (117) Prüßmann J, Prüßmann W, Recke A, Rentzsch K, Juhl D, Henschler R, Müller S, Lamprecht P, **Schmidt E**, Csernok E, Görg S, Stöcker W, Zillikens D, Ibrahim S, Ludwig R. Co-occurrence of autoantibodies in healthy blood donors. *Exp Dermatol* 2014, 23: 519-21. IF 4.1
- (118) Langenhan J, Dworschak J, Saschenbrecker S, Komorowski L, Schlumberger W, Stöcker W, Westermann J, Recke A, Zillikens D, **Schmidt E**, Probst C. Specific immunoabsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. *Exp Dermatol* 2014, 23: 253-9. IF 4.1
- (119) Ludwig R, Borradori L, Diaz L, Hashimoto T, Hertl M, Ibrahim S, Jonkman M, Kitajima Yasuo, Murrell D, **Schmidt E**, Shimizu H, Stanley J, Woodley D, Zillikens D. From epidemiology and genetics to diagnostics, outcome measures and novel treatments in autoimmune bullous diseases. *J Invest Dermatol* 2014, 134: 2298-300. IF 7.2
- (120) Yu X, Zheng J, Collin M, **Schmidt E**, Zillikens D, Petersen F. EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils. *Plos One* 2014, 9: e85317. IF3.7
- (121) Samavedam U, Iwata H, Müller S, Schulze FS, Recke A, **Schmidt E**, Zillikens D, Ludwig R. GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita. *J Immunol* 2014, 192: 559-71. IF 5.5
- (122) Sayar B, Rüegg S, **Schmidt E**, Sibilila M, Siffert M, Suter M, Galichet A, Mueller E. EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. *Exp Dermatol* 2014, 23: 33-8. IF 4.1
- (123) Komorowski L, Müller R, Vorobyev A, Probst C, Recke A, Jonkman MF, Hashimoto T, Kim SC, Groves R, Ludwig R, Zillikens D, Stöcker W, **Schmidt E**. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. *J Am Acad Dermatol* 2013, 68: 89-95. IF 4.9
- (124) Schulze F, van Beek N, Terheyden P, Zillikens D, **Schmidt E**. Concomitant bullous pemphigoid and dermatitis herpetiformis. *Dermatology* 2013, 226: 217-21. IF 2.0
- (125) Van Beek N, Schumacher N, Haase O, Zillikens D, Kahle B, **Schmidt E**. Diagnose eines Antiphospholipidsyndroms bei Ulcus cruris unter Marcumartherapie. *Hautarzt* 2013, 64: 666-70. IF 0.5

- (126) Tukaj S, Kleszczyński K, Vafia K, Groth S, Meyersburg D, Trzonkowski p, Ludwig R, Zillikens D, **Schmidt E**, Fischer T, Kasperkiewicz M. Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. *Plos One* 2013, 8:e70496. IF3.7
- (127) Hellberg L, Samavedam U, Holdorf K, Hänsel M, Recke A, Beckmann T, Steinhorst K, Boehncke WH, Kirchner T, Möckel N, Solbach W, Zillikens D, **Schmidt E**, Ludwig R, Laskay T. Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. *J Invest Dermatol* 2013, 133:2390-99. IF 6.2
- (128) Spindler V, Rötzer V, Dehner C, Kempf B, Gliem M, Hartlieb E, Harms GS, **Schmidt E**, Waschke J. Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. *J Clin Invest* 2013, 123: 800-811. IF 12.8
- (129) Tukaj S, **Schmidt E**, Ludwig R, Zillikens D, Tukaj C, Kasperkiewicz. Vitamin D status in bullous pemphigoid patients. *Br J Dermatol* 2013, 168: 873-74. IF 3.8
- (130) Majima Y, Yagi H, Tateishi C, Groth S, **Schmidt E**, Zillikens D, Koga H, Hashimoto T, Tokura Y. A successful treatment with ustekinumab in a case of anti-laminin- $\gamma$ 1 pemphigoid associated with psoriasis. *Br J Dermatol* 2013, 168: 1367-69. IF 3.8
- (131) Kamiya K, Aoyama Y, Kawase K, **Schmidt E**, Zillikens D, Kitajima Y, Iwatsuki K. Case of subepidermal blistering disease with autoantibodies to both laminin- $\gamma$ 1 and laminin- $\alpha$ 3. *J Dermatol* 2013; 40: 491-2. IF 2.1
- (132) Kim JH, Kim YH, Kim S, Noh EB, Kim SE, Vorobyev A, **Schmidt E**, Zillikens D, Kim SC. Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. *J Eur Acad Dermatol Venereol* 2013, 27: 224-230. IF 2.7
- (133) Hirose M, Vafia K, Kalies K, Groth S, Westermann J, Zillikens D, Ludwig R, Collin M, **Schmidt E**. Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII. *J Autoimmun* 2012, 39: 304-14. IF 8.1
- (134) Vafia K, Groth S, Beckmann T, Hirose M, Dworschak J, Recke A, Ludwig R, Hashimoto T, Zillikens D, **Schmidt E**. Pathogenicity of autoantibodies in anti-p200 pemphigoid. *Plos One* 2012, 7: e41769. IF 3.7
- (135) van Beek N, Rentzsch K, Probst C, Komorowski L, Kasperkiewicz M, Fechner K, Bloecker IM, Zillikens D, Stöcker W, **Schmidt E**. Serological diagnosis of autoimmune bullous skin diseases: Prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. *Orphanet J Rare Dis* 2012, 7:49. IF 4.3
- (136) Groth S, Vafia K, Recke A, Dähnrich C, Zillikens D, Stöcker W, Kuhn A, **Schmidt E**. Antibodies to the C-terminus of laminin  $\gamma$ 1 are present in a distinct subgroup of patients with systemic and cutaneous lupus erythematosus. *Lupus* 2012, 21: 1482-83. IF 2.8
- (137) Monshi B, Groth S, Richter L, **Schmidt E**, Zillikens D, Rappersberger K. A long-term study of a patient with anti-p200 pemphigoid - correlation of autoantibody levels with disease activity and an example of epitope spreading. *Br J Dermatol* 2012, 167: 1179-1183. IF 3.8
- (138) Kamphausen I, Schulze F, **Schmidt E**, Zillikens D, Kunz M. Treatment of severe pemphigus vulgaris with adjuvant rituximab and immunoadsorption. *Eur J Dermatol* 2012, 22: 786-87. IF 1.8
- (139) Samavedam U, Kalies K, Scheller J, Gupta Y, Jonkman MF, **Schmidt E**, Westermann J, Zillikens D, Rose-John S, Ludwig R. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. *J Autoimmun* 2012, 40: 74-85. IF 8.1
- (140) Kasperkiewicz M, Nimmerjahn F, Wende S, Hirose M, Iwata H, Jonkman M, Samavedam U, Gupta Y, Möller S, Rentz E, Hellberg L, Kalies K, Yu Y, **Schmidt E**, Häsler R, Laskay T, Westermann J, Köhl J, Zillikens D, Ludwig R. Genetic identification and functional validation of Fc $\gamma$ RIV as key molecule in autoantibody-induced tissue injury. *J Pathol* 2012, 228: 8-19. IF 7.6

- (141) Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, von Wussow P, Hertl M, Zillikens D, Freivogel K, Dörner T, **Schmidt E**. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. *J Dtsch Dermatol Ges* 2012, 10: 727-32. IF 1.5
- (142) Blöcker IM, Dähnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stöcker W, Zillikens D, **Schmidt E**. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. *Br J Dermatol* 2012, 166: 964-70. IF 3.8
- (143) Dworschak J, Recke A, Freitag M, Ludwig R, Langenhan J, Kreuzer OJ, Zillikens D, **Schmidt E**. Mapping of B cell epitopes on desmoglein 3 in pemphigus vulgaris patients by the use of overlapping peptides. *J Dermatol Sci* 2012, 65: 102-9. IF 3.5
- (144) Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, Israeli S, Sagiv N, Martinez H, Katz O, Baum S, Barzilai A, Trau H, Murrell DF, Bergman R, Hertl M, Rosenberg S, Nöthen MM, Skorecki K, **Schmidt E**, Zillikens D, Darvasi A, Geiger D, Rosset S, Ibrahim SM, Sprecher E. A population-specific variant in *ST18*, encoding a pro-apoptotic molecule, predisposes to pemphigus vulgaris; *J Invest Dermatol* 2012, 132: 1798-805. IF 6.2
- (145) Ludwig R, Müller S, de Castro Marques A, Recke A, **Schmidt E**, Zillikens D, Möller S, Ibrahim S. Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita. *J Invest Dermatol* 2012, 132: 1409-15. IF 6.2
- (146) van Beek N, Knuth-Rehr D, Altmeyer P, Assaf C, Babilas , Bayerl C, Benoit S, Dippel E, Effendy I, Eming R, Fischer M, Glaenz T, Gläser R, Goebeler M, Gollnick H, Götze S, Gross P, Hadaschik E, Herbst R, Hermes B, Homey B, Hunzelmann N, Jünger M, Kapp M, Kern JS, Körber A, Luger T, Mechtel D, Megahed M, Moll I, Peters KP, Pfeiffer C, Ring J, Röcken M, Sárdy M, Seitz C, Stadler R, Steinbrink K, Sticherling M, Szeimies RM, Tronnier M, Ulrich J, Vogt T, Wagner N, Welzel J, Wenzel J, Wozel G, Zouboulis CC, Zillikens D, **Schmidt E**. Diagnostic of autoimmune bullous diseases in German dermatology departments. *J Dtsch Dermatol Ges* 2012, 10: 492-99. IF 1.4
- (147) Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha A, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman M, Pandya A, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM, **Schmidt E**, Shimizu H, Zone J, Swerlick R, Culton D, Mimouni D, Lipozencic J, Bincie B, Bystryn JC, Werth VP. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. *J Am Acad Dermatol* 2012, 66: 479-85. IF 4.9
- (148) Westermann L, Huegel R; Meier M, Zillikens D, Glaeser R, **Schmidt E**. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoabsorption. *J Dermatol* 2012, 39: 168-71. IF 1.8
- (149) Schulz S, Deuster D, **Schmidt E**, Bonsmann G, Beissert S. Therapeutic effect of etanercept in anti-laminin 5 (laminin 332) mucous membrane pemphigoid. *Int J Dermatol* 2011, 50: 1129-31. IF 1.3
- (150) Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, Zillikens D, **Schmidt E**. Treatment of severe pemphigus with a combination of immunoabsorption, rituximab, pulsed dexamethasone, and azathioprine/ mycophenolate mofetil: a pilot study of 23 patients. *Br J Dermatol* 2012, 166: 154-60. IF 4.4
- (151) Spindler V, Endlich A, Hartlieb E, Vielmuth E, **Schmidt E**, Waschke J. The extent of desmoglein 3 depletion in pemphigus vulgaris is dependent on Ca<sup>2+</sup>-induced differentiation – a role in suprabasal epidermal skin splitting? *Am J Pathol* 2011, 179: 1905-16. IF 4.8
- (152) Kasperkiewicz M, Müller R, Manz R, Magens M, Hammers CM Somlai C, Westermann J, **Schmidt E**, Zillikens D, Ludwig RJ, Orosz A. Heat shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that non-malignant plasma cells are not therapeutic targets. *Blood* 2011, 117: 135-42. IF 9.9

- (153) Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K, Westermann J, Zillikens D, **Schmidt E**, Ludwig R. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. *J Immunol* 2011, 187: 1176-83. IF 5.8
- (154) Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Muller-Ladner U, Koenig R, Fiehn C, Burgwinkel P, Budde K, Soerensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, **Schmidt E**, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dorner T. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). *Arthritis Res Ther* 2011, 13: R75. IF 4.4
- (155) Saleh MA, Ishii K, Kim YJ, Murakami A, Ishii N, Hashimoto T, **Schmidt E**, Zillikens D, Shirakata Y, Hashimoto K, Kitajima Y, Amagai M. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. *J Dermatol Sci* 2011, 62: 169-75. IF 3.7
- (156) Recke A, Shimanovich I, Steven P, Westermann L, Zillikens D, **Schmidt E**. Therapieresistentes Anti-Laminin 332-Schleimhautpemphigoid: Komplette Remission unter adjuvanter Immunapherese und Rituximab. *Hautarzt* 2011, 62: 852-8. IF 0.6
- (157) Haase O, Moser A, Rose C, Kurth A, Zillikens D, **Schmidt E**. Generalised cowpox infection in a patient with Darier's disease. *Br J Dermatol* 2011, 164: 1116-8. IF 3.7
- (158) Westermann L, Dilling A, Pajouh P, Rose C, **Schmidt E**. Longstanding painful hemorrhagic vesicles and erosions on the lower leg. *Arch Dermatol* 2011, 147:235-40. IF 3.9
- (159) Groth S, Recke A, Vafia K, Ludwig R, Hashimoto T, Zillikens D, **Schmidt E**. Development of a simple ELISA for the detection of autoantibodies in anti-p200 pemphigoid. *Br J Dermatol* 2011, 164:76-82. IF 3.7
- (160) Kasperkiewicz M, Shimanovich I, Ludwig R, Rose C, Zillikens D, **Schmidt E**. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. *J Am Acad Dermatol* 2011, 65: 552-8. IF 4.0
- (161) Leverkus M, Ambach A, Hoefeld-Fegeler M, Kohlhase J, **Schmidt E**, Schumann H, Has C, Gollnick H. Late onset inversa recessive dystrophic epidermolysis bullosa caused by glycine substitutions in collagen type VII. *Br J Dermatol* 2011, 164:1104-6. IF 3.7
- (162) Saw V, Offiah I, Galatowicz G, **Schmidt E**, Zillikens D, Dart J, Calder VL, Daniels JT. Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid. *Am J Pathol* 2011, 178: 187-97. IF 4.8
- (163) Ludwig RJ, Recke A, Bieber K, Müller S, de Castro Marques A, Banczyk D, Hirose M, Kasperkiewicz M, Ishii N, **Schmidt E**, Westermann J, Zillikens D, Ibrahim SM. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. *J Invest Dermatol* 2011, 131: 167-76. IF 6.3
- (164) Kasperkiewicz M, **Schmidt E**, Frambach Y, Rose C, Meier M, Nitschke M, Falk TM, Reich K, Ludwig R, Zillikens D. Improvement of treatment-refractory atopic dermatitis by immunoabsorption: A pilot study. *J Allergy Clin Immunol* 2011, 127: 267-70. IF 11.0
- (165) Spindler V, Vielmuth F, **Schmidt E**, Rubenstein DS, Waschke J. Protective endogenous cAMP signaling triggered by pemphigus autoantibodies. *J Immunol* 2010, 185:6831-8. IF 5.7
- (166) Kubisch I, Diessenbacher P, **Schmidt E**, Gollnick H, Leverkus M. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis. *Am J Clin Dermatol* 2010, 11: 289-93. IF 2.0
- (167) Kasperkiewicz M, Hirose M, Recke A, **Schmidt E**, Zillikens D, Ludwig RJ. Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. *Br J Dermatol* 2010, 162: 1064-70. IF 4.3

- (168) Kasperkiewicz M, Meier M, Zillikens D, **Schmidt E**. Linear IgA disease: successful application of immunoadsorption and review of the literature. *Dermatology* 2010, 220:259-63. IF 2.7
- (169) Kasperkiewicz M, Hoppe U, Zillikens D, **Schmidt E**. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. *Clin Exp Dermatol* 2010, 25:614-17. IF 1.3
- (170) Zimmermann J, Bahmer F, Rose C, Zillikens D, **Schmidt E**. Clinical and immunopathological spectrum of paraneoplastic pemphigus. *J Dtsch Dermatol Ges* 2010, 8:598-603. IF 1.5
- (171) **Schmidt E**, Dähnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stöcker W, Hashimoto T, Bröcker EB, Recke A, Rose C, Zillikens D. Novel ELISA systems for antibodies to desmoglein 1 and 3: Correlation of disease activity with serum autoantibody levels in individual pemphigus patients. *Exp Dermatol* 2010, 19: 458-63. IF 4.2
- (172) Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Schulze-Lohoff E, Becker M, Sunderkoetter C; Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, **Schmidt E**, Lehmann P, Foeldvári I, Reichenberger F, Gross L, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V, Buslau M, Distler J, Sticherling M, Riemekasten G. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations: an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. *Rheumatology (Oxford)*. 2009; 48: 70-73. IF 4.1
- (173) Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G; Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Mierau R, Hein R, Hinrichs R, Szeimies RM, Karrer S, Muller AM, Meyering R, Seitz C, **Schmidt E**, Lehmann P, Foeldvari I, Reichenberger F, Gross L, Kuhn A, Haust M, Reich K, Becker M, Saar P, Schmeiser T, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Grafenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V, Buslau M, Distler J, Sticherling M. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. *Br J Dermatol* 2009;160: 835-43. IF 4.3
- (174) Probst C, Schlumberger W, Stöcker W, Recke A, **Schmidt E**, Hashimoto T, Zhu XJ, Zillikens D, Komorowski L. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. *Clin Chim Acta* 2009, 410: 13-8. IF 2.5
- (175) Riederle HM, **Schmidt E**, Eck M, Meyer-ter-Vehn T, Geerling G. Tumour of the conjunctiva with diffuse cicatrisation. *Ophthalmologie*. 2009;106: 56-9. IF 0.8
- (176) Spindler V, Heupel WM, Efthymiadis A, **Schmidt E**, Eming R, Rankl C, Hinterdorfer P, Müller T, Drenckhahn D, Waschke J. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus. *J Biol Chem* 2009; 284: 30556-64. IF 5.3
- (177) Heupel WM, Mueller TD, Efthymiadis A, **Schmidt E**, Drenckhahn D, Waschke J. Peptides targeting the desmoglein 3 adhesive interface prevent autoantibody-induced acantholysis in pemphigus. *J Biol Chem* 2009; 284: 8589-95. IF 5.3
- (178) Heupel WM, Engerer P, **Schmidt E**, Waschke J. Pemphigus vulgaris IgG cause loss of desmoglein-mediated adhesion and keratinocyte dissociation independent of epidermal growth factor receptor. *Am J Pathol*. 2009; 174: 475-85. IF 5.7
- (179) Recke A, Rose C, **Schmidt E**, Bröcker EB, Zillikens D, Sitaru C. Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B cell epitope spreading without IgG subclass shifting. *J Am Acad Dermatol* 2009; 61: 333-36. IF 4.1
- (180) Schumann T, **Schmidt E**, Booken M, Goerdts S, Goebeler M. Successful treatment of mucous membrane pemphigoid with the anti-CD20 antibody rituximab. *Acta Dermatol Venereol (Stockh.)* 2009, 89: 101-2. IF 3.0

- (181) Rose C, **Schmidt E**, Kerstan A, Thoma-Uszynski S, Wesselmann U, Käsbohrer U, Zillikens D, Shimanovich I. Histopathology of anti-laminin 5 mucous membrane pemphigoid. *J Am Acad Dermatol*. 2009, 61: 433-40. IF 4.1
- (182) Bertram F, Bröcker EB, Zillikens D, **Schmidt E**. Prospektive Untersuchung der Inzidenz blasenbildender Autoimmundermatosen in Unterfranken. *J Dtsch Dermatol Ges* 2009, 5: 434-40. IF 1.4
- (183) **Schmidt E**, Benoit S, Bröcker E. Umbilical bullous pemphigoid. *Acta Dermatol Venereol (Stockh.)*, 2009, 89: 419-20. IF 3.0
- (184) **Schmidt E**, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. *Clin Immunol* 2009;132: 334-41. IF 3.9
- (185) **Schmidt E**, Gutberlet J, Siegmund D, Berg D, Wajant H, Waschke J. Apoptosis is not required for acantholysis in pemphigus vulgaris. *Am J Physiol Cell Physiol* 2009; 296, C162-172. IF 4.0
- (186) Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, **Schmidt E**, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. *Rheumatology (Oxford)* 2008; 47: 1185-92. IF 4.1
- (187) Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, **Schmidt E**, Shimanovich I, Sticherling M, Wolff-Franke S. Empfehlungen für den Einsatz von Rituximab (anti-CD20 -Antikörper) bei bullösen Autoimmundermatosen. *J Dtsch Dermatol Ges* 2008; 6: 366-74. IF 1.4
- (188) Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M, Hofmann SC, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, **Schmidt E**, Shimanovich I, Sticherling M, Ziller M. Recommendations for the use of immunoadsorption in the treatment of autoimmune bullous diseases. *J Dtsch Dermatol Ges* 2007; 5: 881-7. IF 1.4
- (189) Sitaru C, Dähnrich D, Probst C, Komorowski L, Blöckere I, **Schmidt E**, Schlumberger W, Rose C, Stöcker W, Zillikens D. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. *Exp Dermatol* 2007; 16: 770-777. IF 3.0
- (190) Kerstan A, Goebeler M, **Schmidt E**, Bröcker EB, Schön P. Lupus erythematosus profundus in an 8-year-old child. *J Eur Acad Dermatol Venerol* 2007; 21: 132-3. IF 1.4
- (191) **Schmidt E**, Tony HP, Bröcker EB, Kneitz C. Sun-induced life-threatening lupus-nephritis. *Ann N Y Acad Sci* 2007; 1108: 35-40. IF 1.7
- (192) **Schmidt E**, Vetter-Kauczok CS, Kolb-Mäurer A, Mooi W, Bröcker EB. Indurated swelling of the scrotum in a 65-year-old man. *Clin Exp Dermatol* 2007; 32: 588-589. IF 1.5
- (193) **Schmidt E**, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. *Br J Dermatol* 2007; 156: 352-6. IF 3.6
- (194) Mulyowa GK, Jaeger G, Sitaru C, Bröcker E-B, Zillikens D, **Schmidt E**. Scarring autoimmune bullous disease in an Ugandan patient with autoantibodies to BP180, BP230, and Laminin 5. *J Am Acad Dermatol* 2006; 54: S43-46. IF 2.6
- (195) Mulyowa GK, Jaeger G, Kabakyenga J, Bröcker EB, Zillikens D, **Schmidt E**. Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. *Int J Dermatol* 2006; 45:1047-52. IF 1.0

- (196) Shimanovich I, Herzog S, **Schmidt E**, Klinker E, Opitz A, Bröcker EB, Goebeler M, Zillikens D. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. *Clin Exp Dermatol* 2006; 31: 768-74. IF 1.3
- (197) Benoit S, **Schmidt E**, Sitaru S, Rose C, Goebeler M, Bröcker E-B, Zillikens D. Schleimhautpemphigoid mit Autoantikörpern gegen Laminin 5. *J Dtsch Dermatol Ges* 2006; 4: 41-44. IF 1.4
- (198) **Schmidt E**, Wehr B, Wolf K, Sitaru C, Bröcker EB, Zillikens D. Localisation of Bullous Pemphigoid Antigen 180 (BP180) in cultured human keratinocytes: functionally relevant modification by calcium. *Arch Dermatol Res* 2006; 298: 283-90. IF 1.6
- (199) **Schmidt E**, Weissbrich B, Bröcker E-B, Fleischer K, Goebeler M, Stich G. Orf followed by erythema multiforme. *J Eur Acad Dermatol Venerol* 2006; 18: 612-13. IF 1.5
- (200) **Schmidt E**, Benoit S, Bröcker E-B, Zillikens D, Goebeler M. Successful treatment of recalcitrant epidermolysis bullosa acquisita with rituximab. *Arch Dermatol* 2006; 142: 47-50. IF 2.9
- (201) **Schmidt E**, Herzog S, Bröcker E-B, Zillikens D, Goebeler M. Rituximab induced long-standing remission in a 14-year-old boy with treatment-resistant pemphigus vulgaris. *Br J Dermatol* 2005; 153: 449-451. IF 3.0
- (202) **Schmidt E**, Kraensel R, Goebeler M, Sinkgraven R, Bröcker EB, Rzany B, Zillikens D. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. *Cutis* 2005, 76: 205-209. IF 0.9
- (203) Herzog S, **Schmidt E**, Goebeler M, Bröcker EB, Zillikens D. Serum Levels of Autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. *Acta Dermatol Venereol (Stockh.)* 2004; 84: 48-52. IF 1.9
- (204) **Schmidt E**, Rose C, Mulyowa GK, Jäger G. Dermatologie an der Universitäts-Hautlinik Mbarara, Uganda. *J Dtsch Dermatol Ges* 2004; 2: 920-926. IF 1.4
- (205) **Schmidt E**, Wehr B, Tabengwa EM, Reimer S, Bröcker EB, Zillikens D. Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. *Clin Exp Immunol* 2004; 135: 497-504. IF 2.5
- (206) Benoit S, Rose C, **Schmidt E**, Zillikens D. Persistierende Papulopusteln im Gesicht eines 21-jährigen. *J Dtsch Dermatol Ges* 2003, 1: 907-909. IF 1.4
- (207) **Schmidt E**, Rose C, Benoit S, Hamm H. Multiple Papeln und Knoten am Skrotum eines 34-jährigen Patienten. *J Dtsch Dermatol Ges* 2003, 1: 395-397. IF 1.4
- (208) **Schmidt E**, Kromminga A, Kürschner M, Zimmermann H, Katsen AD, Bröcker EB, Zillikens D, Zimmermann U, Sukhorukov VL. Trehalose conserves expression of bullous pemphigoid antigen 180 during desiccation and freezing. *J Immunol Meth* 2003, 275: 179-190. IF 2.7
- (209) **Schmidt E**, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M, BM Taleghoni, Bröcker EB, Zillikens D. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. *Br J Dermatol* 2003, 148: 1222-1229. IF 2.7
- (210) Kromminga A, Sitaru C, Meyer J, Arndt R, **Schmidt E**, Christophers E, Bröcker EB, Zillikens D. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain. *J Dermatol Sci* 2002; 28: 68-75. IF 1.6
- (211) Sitaru C, **Schmidt E**, Petermann, Munteanu LS, Bröcker EB, Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. *J Invest Dermatol* 2002; 118: 664-671. IF 4.3
- (212) **Schmidt E**, Kromminga A, Mimiety S, Leinfelder U, Sitaru C, Bröcker EB, Zillikens D, Zimmermann U. A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. *J Autoimmunity* 2002, 18: 299-309. IF 2.3

- (213) **Schmidt E**, Höpfner B, Chen M, Kuhn C, Weber L, Bröcker EB, Bruckner-Tuderman L, Zillikens D. Childhood epidermolysis bullosa acquisita: a novel variant with reactivity to all three structural domains of type VII collagen. *Br J Dermatol* 2002, 147: 592-597. IF 2.7
- (214) **Schmidt E**, Sitaru C, Schubert B, Wesselmann U, Kromminga A, Bröcker EB, Zillikens D. Subacute prurigo variant of bullous pemphigoid: autoantibodies show the same specificity compared to classical bullous pemphigoid. *J Am Acad Dermatol* 2002, 47: 133-136. IF 2.8
- (215) Zillikens D, **Schmidt E**, Reimer S, Chimanovitch I, Hardt-Weinelt K, Rose C, Bröcker E-B, Koch M, Böhnke WH. Antibodies to desmoglein 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. *J Pathol* 2001; 193: 117-124. IF 4.9
- (216) **Schmidt E**, Leinfelder U, Geßner P, Zillikens D, Bröcker EB, Zimmermann U. CD19<sup>+</sup> B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. *J Immunol Meth* 2001; 255: 93-102. IF 2.7
- (217) **Schmidt E**, Skrobek C, Kromminga A, Hashimoto T, Messer G, Bröcker E-B, Yancey KB, Zillikens D. Cicatricial Pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of BP180. *Br J Dermatol* 2001; 145: 778-783. IF 2.6
- (218) **Schmidt E**, Reimer S, Kruse N, Bröcker EB, Zillikens D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. *Clin Exp Immunol* 2001; 142: 157-162. IF 2.3
- (219) Döpp R, **Schmidt E**, Chimanovitch I, Leverkus M, Bröcker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. *J Am Acad Dermatol* 2000; 42: 577-83. IF 2.5
- (220) **Schmidt E**. Dermatologie im Sahel: Eindrücke einer Hospitation im Tschad. *Dt Dermatol* 2000, 5: 357-359. IF 0.25
- (221) **Schmidt E**, Reimer S, Kruse N, Jainta S, Bröcker E-B, Marinkovich MP, Giudice GJ, Zillikens D. Autoantibodies to BP180 associated with bullous pemphigoid release IL-6 and IL-8 from cultured human keratinocytes. *J Invest Dermatol* 2000, 115: 842-848. IF 4.5
- (222) **Schmidt E**, Obe K, Bröcker E-B, Zillikens D. Levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. *Arch Dermatol* 2000, 136: 174-178. IF 3.5
- (223) Zillikens D, Caux F, Mascaro JM, Prost C, Wesselmann U, **Schmidt E**, Prost C, Callen JP, Bröcker EB, Diaz LA, Giudice GJ. Antibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. *J Invest Dermatol* 1999; 113: 117-121. IF 4.5
- (224) Zillikens D, Herzele K, Georgi M, **Schmidt E**, Chimanovitch I, Schumann H, Mascaro JM Jr, Diaz LA, Bruckner-Tuderman L, Bröcker EB, Giudice GJ. Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP180. *J Invest Dermatol* 1999; 113: 947-53. IF 4.5
- (225) Kippes W, **Schmidt E**, Roth A, Rzany B, Bröcker EB, Zillikens D. Immunopathologic changes in 115 patients with bullous pemphigoid. *Hautarzt*. 1999; 50: 866-72. IF 0.5
- (226) Chimanovitch I, **Schmidt E**, Messer G, Döpp R, Portscht K, Bröcker EB, Giudice GJ, Zillikens D. IgG<sub>1</sub> and IgG<sub>3</sub> are the major immunoglobulin subclasses targeting epitopes within BP180 NC16A in pemphigoid gestationis. *J Invest Dermatol* 1999; 113: 10-142. IF 4.5
- (227) Leverkus M, **Schmidt E**, Lazarova Z, Bröcker EB, Yancey KB, Zillikens D. Anti-epiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring subepidermal bullous diseases. *Arch Dermatol* 1999, 135: 1091-1098. IF 3.5
- (228) **Schmidt E**, Herzele K, Schumann H, Wesselmann U, Chimanovitch I, Bruckner-Tuderman L, Bröcker E-B, Giudice GJ, Zillikens D. Linear IgA disease with circulating IgA antibodies against the NC16A domain of BP180. *Br J Dermatol* 1999; 140: 964-967. IF 2.6
- (229) **Schmidt E**, Ambach A, Bastian B, Bröcker E-B, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy controls. *J Am*



Acad Dermatol 1996; 34: 310-313. IF 2.8

- (230) **Schmidt E**, Bastian B, Dummer R, Tony HP, Bröcker E-B, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996; 288: 353-357. IF 1.6
- (231) **Schmidt E**, Mittnacht A, Schömig H, Dummer R, Bröcker E-B, Zillikens D. Detection of IL-1 $\alpha$ , IL-1 $\beta$ , and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. J Dermatol Sci 1996; 11: 142-147. IF 1.6
- (232) **Schmidt E**, Bröcker E-B, Zillikens. High levels of soluble CD23 in blister fluid of bullous pemphigoid. Arch Dermatol 1995; 131: 966-967. IF 3.5

**IF gesamt: 1.110,3**

## Reviews in peer-reviewed journals

- (1) Sadik C, **Schmidt E**, Zillikens D, Hashimoto T. Recent progress and perspectives in autoimmune bullous diseases. *J Allergy Clin Immunol* 2020, 145: 1145-47. IF 10.2
- (2) Drenovska K, **Schmidt E**, Vassileva S. Covid-19 pandemic and the skin. *Int J Dermatol*, in press. IF 2.1
- (3) van Beek N, **Schmidt E**, Zillikens D. Moderne Diagnostik bullöser Autoimmundermatosen. *Pathologe*, in press. IF 0.6
- (4) **Schmidt E**, Kasperkiewicz M, Joly P. Pemphigus. *Lancet* 2019, 394: 882-894. IF 60.4
- (5) Sadik C, **Schmidt E**. Resolution in bullous pemphigoid. *Semin Immunopathol* 2019, 41: 645-54. IF 7.5
- (6) van Beek N, Zillikens D, **Schmidt E**. Therapie des Pemphigus. *Hautarzt* 2019, 70: 243-53. IF 0.7
- (7) Eming R, **Schmidt E**. Bullöse Autoimmundermatosen: Update zu Therapien und selteneren Entitäten (editorial). *Hautarzt* 2019, 70: 234-35. IF 0.7
- (8) van Beek N, Zillikens D, **Schmidt E**. Diagnosis of autoimmune bullous diseases. *J Dtsch Dermatol Ges* 2018, 16: 1077-92. IF 3.9
- (9) Witte M, Zillikens D, **Schmidt E**. Diagnosis of autoimmune blistering diseases. *Front Med* 2018, 5: 296. IF 3.1
- (10) Holtsche M, Zillikens D, **Schmidt E**. Mucous membrane pemphigoid. *Hautarzt* 2018: 67-83. IF 0.7
- (11) Amber KT, Murrell DF, **Schmidt E**, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. *Clin Rev Allergy Immunol* 2018, 54: 26-51. IF 7.3
- (12) Goletz S; Zillikens D, **Schmidt E**. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. *Exp Dermatol* 2017, 26: 1154-62. IF 2.6
- (13) Vorobyev A, Ludwig R, **Schmidt E**. Clinical features and diagnosis of epidermolysis bullosa acquisita. *Expert Rev Clin Immunol* 2017, 13: 157-69. IF 3.4
- (14) Försti AK, Huilaja L, **Schmidt E**, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid - more than skin deep? *Exp Dermatol* 2017, 26: 1228-34. IF 2.6
- (15) Ludwig R, Vanhoorelbeke K, Leyboldt F, Kaya Z, Bieber K, McLachlan S, Komorowski L, Luo J, Marques O, Hammers CM, Lindstrom JM, Lamprecht P, Fischer A, Riemekasten G, Tersteeg C, Sondermann P, Rapoport B, Wandinger KP, Probst C, El Beidaq A, **Schmidt E**, Verkman A, Manz R, Nimmerjahn F. Mechanisms of autoantibody-induced pathology. *Front Immunol* 2017, 8: 603. IF 5.5
- (16) Lima AL, Zillikens D, **Schmidt E**. Klinik und Diagnostik bullöser Autoimmundermatosen: wenn die Schleimhaut nicht mehr heilen will. *ZM* 2016, 106: 72-84. IF 0.25
- (17) Van Beek N, Schulze FS, Zillikens D, **Schmidt E**. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. *Expert Rev Clin Immunol* 2016, 12: 267-77. IF 3.3
- (18) Kasperkiewicz M, Sadik C, Bieber K, Ibrahim S, Manz R, **Schmidt E**, Zillikens D, Ludwig R. Epidermolysis bullosa acquisita: From pathophysiology to novel therapeutic options. *J Invest Dermatol* 2016, 136: 24-33. IF 6.9
- (19) Stockinger T, Richter L, Kanzler M, Melichart-Kotik M, Pas H, Derfler K, **Schmidt E**, Rappersberger K. Systemischer Lupus erythematosus: ungewöhnliche Hautmanifestationen. *Hautarzt* 2016, 67: 970-81. IF 0.6
- (20) Vorobyev A, Hammers C, Zillikens D, **Schmidt E**. Bullöse Autoimmundermatosen: Moderne serologische Testverfahren ermöglichen genaue Diagnose. *Dtsch Dermatol* 2015, 63: 738-745. IF 0.25

- (21) Goletz S, Hashimoto T, Zillikens D, **Schmidt E**. Anti-p200 pemphigoid. *J Am Acad Dermatol* 2014, 71: 185-91. IF 4.9
- (22) Schwieger-Briel A, Moellmann C, Mattulat B, Schauer F, Kiritsi D, **Schmidt E**, Sitaru C, Ott H, Kern JS. Bullous pemphigoid in infants: characteristics, diagnosis and treatment. *Orphanet J Rare Dis.* 2014; 9: 185. IF 3.9
- (23) Hammers CM, **Schmidt E**, Zillikens D. Blasenbildende Autoimmunerkrankungen der Haut - diagnostische und therapeutische Aspekte. *DMW* 2014, 139: 1473-77. IF 0.25
- (24) **Schmidt E**, Zillikens D. Pemphigoid diseases. *Lancet* 2013, 381: 320-32. IF 39.2
- (25) Schulze F, Kasperkiewicz M, Zillikens D, **Schmidt E**. Bullöses Pemphigoid. *Hautarzt* 2013, 64: 931-43. IF 0.5
- (26) Ludwig R, Kalies K, Köhl J, Zillikens D, **Schmidt E**. Emerging treatments for pemphigoid diseases. *Trends Mol Med* 2013, 19: 501-12. IF 9.6
- (27) Hammers C, Lunardon L, **Schmidt E**, Zillikens D. Contemporary management of pemphigus. *Exp Opin Orphan Drugs* 2013, 1: 295-314. IF 0.25
- (28) Meyersburg D, **Schmidt E**, Kasperkiewicz M, Zillikens D. Immunoabsorption in dermatology. *Ther Apher Dial* 2012, 16: 311-20. IF 1.5
- (29) Kasperkiewicz, Zillikens D, **Schmidt E**. Pemphigoid diseases: pathogenesis, diagnosis and treatment. *Autoimmunity* 2012, 45: 55-70. IF 2.8
- (30) **Schmidt E**, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. *Dermatol Clin* 2011, 29: 427-38. IF 2.2
- (31) **Schmidt E**, Zillikens D. Diagnosis and treatment of patients with autoimmune bullous disorders in Germany. *Dermatol Clin* 2011, 29: 663-71. IF 2.2
- (32) Kasperkiewicz M, **Schmidt E**, Zillikens D. Current therapy of pemphigus group. *Dermatol Clin* 2011, 30: 84-94. IF 2.2
- (33) **Schmidt E**, Zillikens D. Diagnosis and treatment of autoimmune blistering skin diseases. *Dtsch Arztebl Int* 2011, 108: 399-405. IF 2.9
- (34) Haase O, **Schmidt E**. Pemphigus vulgaris. *Internist Prax* 2011, 51: 295-308. IF 0.25
- (35) **Schmidt E**, Zillikens D. Modern diagnosis of autoimmune blistering diseases. *Autoimmun Rev* 2010, 10: 84-89. IF 6.6
- (36) **Schmidt E**, Zillikens D. Immunoabsorption in dermatology. *Arch Dermatol Res* 2010, 302: 241-53. IF 2.0
- (37) Bieber K, Sun S, Ishii N, Kasperkiewicz M, **Schmidt E**, Hirose M, Westermann J, Yu X, Zillikens D, Ludwig RJ. Animal models for autoimmune bullous dermatoses. *Exp Dermatol* 2009, 19:2-11. IF 3.3
- (38) Kasperkiewicz M, **Schmidt E**. Current treatment of autoimmune blistering diseases. *Curr Drug Discov Technol* 2009; 6: 270-280. IF 0.25
- (39) Ludwig RJ, **Schmidt E**. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis? *G Ital Dermatol Venereol* 2009; 144: 339-49. IF 0.25
- (40) **Schmidt E**. Optimizing therapy in patients with severe autoimmune blistering skin diseases. *Hautarzt* 2009; 60: 633-40. IF 0.4
- (41) **Schmidt E**, Zillikens D. Diagnosis and clinical severity markers of bullous pemphigoid. *F100 Medicine Reports* 2009, 1: 15-18. IF 0.3
- (42) **Schmidt E**, Waschke J. Apoptosis in pemphigus. *Autoimmun Rev* 2009, 8: 533-7. IF 6.4
- (43) **Schmidt E**, Zillikens D. Research in practice: diagnosis of subepidermal autoimmune bullous disorders. *J Dtsch Dermatol Ges* 2009; 7: 296-300. IF 1.4
- (44) **Schmidt E**, Goebeler M, Zillikens D. Rituximab in severe pemphigus. *Ann N Y Acad Sci* 2009; 1173: 683-91. IF 1.7

- (45) Meyer-ter-Vehn T, **Schmidt E**, Zillikens D, Geerling G. Therapie des Schleimhautpemphigoid mit okulärer Beteiligung. *Ophthalmologe* 2008, 105: 405-19. IF 0.8
- (46) **Schmidt E**, Meyer-ter-Vehn T, Zillikens D, Geerling G. Klinik, Pathogenese und Diagnostik des Schleimhautpemphigoid mit okulärer Beteiligung. *Ophthalmologe* 2008, 105: 285-298. IF 0.8
- (47) **Schmidt E**, Goebeler M. Use of CD20-directed therapy in autoimmune skin diseases. *Exp Rev Dermatol* 2008, 3: 259-278. IF 0.3
- (48) **Schmidt E**, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. *Clin Rev Allergy Immunol* 2008, 34: 56-64. IF 1.7
- (49) Benoit S, Bröcker EB, **Schmidt E**. Current treatment of pemphigus. *G Ital Dermatol Venereol* 2007; 142: 363-380. IF 0.3
- (50) **Schmidt E**, Hunzelmann N, Zillikens D, Bröcker E-B, Goebeler M. Rituximab in refractory autoimmune bullous diseases. *Clin Exp Dermatol* 2006; 31:503-08. IF 1.3
- (51) Jainta S, **Schmidt E**, Bröcker EB, Zillikens D. Diagnostik und Therapie bullöser Autoimmunerkrankungen der Haut. *Dt Ärztebl* 2001; 98: A 1320-1325. IF 0.3
- (52) **Schmidt E**, Bröcker EB, Zillikens D. Neue Aspekte zur Pathogenese des bullösen Pemphigoid. *Hautarzt* 2000, 51: 637-645. IF 0.5
- (53) **Schmidt E**, Bröcker EB, Zillikens D. Pemphigus: Verlust des desmosomalen Zell-Zell Kontaktes. *Hautarzt* 2000, 51: 309-318. IF 0.5
- (54) **Schmidt E**, Zillikens D. Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. *Adv Dermatol* 2000; 16: 113-157. IF 0.3

**IF gesamt: 224.9**

## Book chapters

- (1) Schumacher N, **Schmidt E**. Bullöse Autoimmundermatosen: Pemphigus-Gruppe. In: von Stebut E, Berneburg M, Maurer M, Steinbrink K (Hrsg.) Facharztprüfung Dermatologie und Venerologie: 1000 kommentierte Prüfungsfragen. 2. Auflage. Thieme, Stuttgart, 2020, 178-185.
- (2) van Beek, **Schmidt E**. Autoimmune bullous diseases. In: Hoeger P, Kinsler V, Yan AC (Hrsg.). Harper's Textbook of Pediatric Dermatology. 4<sup>th</sup> edition. Wiley-Blackwell, 2020, 868-897.
- (3) **Schmidt E**, Groves R. Immunobullous diseases. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (Hrsg.). Rook's Textbook of Dermatology. 9<sup>th</sup> edition. Wiley-Blackwell, 2016, 50.01-50-56.
- (4) **Schmidt E**, Zillikens Z. Immunfluoreszenztechniken. In: Kerl H, Garbe C, Cerroni L, Wolff HH (Hrsg.) Histopathologie der Haut. 2. Auflage. Springer, Heidelberg, 2016, 46-59.
- (5) Schumacher N, Mook SC, Shimanovich I, Zillikens D, **Schmidt E**. Life-threatening pemphigus vulgaris. In: Murrell D (Hrsg.). Clinical cases in autoimmune blistering diseases. Springer, Heidelberg, 2015, 35-43.
- (6) **Schmidt E**, Borradori L, Joly P. Epidemiology of autoimmune bullous diseases. In: Murrell D (Hrsg.). Blistering diseases. 1<sup>st</sup> edition. Springer, Heidelberg, 2015, 251-264.
- (7) **Schmidt E**, Borradori L, Sprecher E, Marinovic B, Sinha AA, Joly P. Genetic and environmental risk factors of autoimmune bullous diseases. In: Murrell D (Hrsg.). Blistering diseases. 1<sup>st</sup> edition. Springer, Heidelberg, 2015, 131-140.
- (8) Hammers C, **Schmidt E**, Borradori L. Pemphigus foliaceus & pemphigus erythematosus. In: Katsambas AD et al. (Hrsg.) European Handbook of Dermatological Treatments. 3rd edition. Springer, Heidelberg, 2015, 691-700.
- (9) Hammers C, **Schmidt E**, Borradori L,. Pemphigus vegetans. In: Katsambas AD et al. (Hrsg.) European Handbook of Dermatological Treatments. 3rd edition. Springer, Heidelberg, 2015, 701-705.
- (10) Schumacher N, **Schmidt E**. Bullöse Autoimmundermatosen: Pemphigus-Gruppe. In: von Stebut E, Berneburg M, Maurer M, Steinbrink K (Hrsg.) Facharztprüfung Dermatologie und Venerologie: 1000 kommentierte Prüfungsfragen. Thieme, Stuttgart, 2014, 153-59.
- (11) **Schmidt E**, Zillikens D. Immunoabsorption treatment for autoimmune bullous diseases. In: (Hrsg.) Braun, N. Fundamentals and applications of immunoabsorption. 2<sup>nd</sup> edition. UNI-MED, Bremen, 2013, 46-59.
- (12) Welzel J, Maier T, Kaatz M, Dissmond J, Körber A, **Schmidt E**. Neue diagnostische und therapeutische Methoden. In: Ruzicka T, Wolff H, Thomas P, Prinz J (Hrsg.) Fortschritte der praktischen Dermatologie und Venerologie 2012. Springer, Heidelberg, 2013, 468-78.
- (13) Welzel J, Kaatz M, Hohenleutner U, **Schmidt E**. Neue diagnostische und therapeutische Methoden. In: Ruzicka T, Wolff H, Thomas P, Prinz J (Hrsg.) Fortschritte der praktischen Dermatologie und Venerologie 2010. Springer, Heidelberg, 2011, 403-12.
- (14) **Schmidt E**, Zillikens D. Immunoabsorption treatment for autoimmune bullous diseases. In: (Hrsg.) Braun, N. Fundamentals and applications of immunoabsorption. UNI-MED, Bremen, 2009.
- (15) **Schmidt E**, Kromminga A, Zillikens D, Zimmermann U. Simple and sensitive detection of serum autoantibodies to full-length bullous pemphigoid antigen 180. In: Conrad K, Fritzler M, Meurer, Sack U, Shoenfeld Y (Hrsg.) From proteomics to molecular epidemiology: relevance of autoantibodies. Pabst, Lengerich, 2002, 71-80.
- (16) **Schmidt E**, Obe K, Giudice GJ, Bröcker EB, Zillikens D. Antikörper gegen BP180 korrelieren mit der Krankheitsaktivität des bullösen Pemphigoids. In: Meigel WN, Moll I, Plettenberg A

(Hrsg.). Dermatologie an der Schwelle zum neuen Jahrtausend. Springer, Heidelberg Berlin 1999, 81-83.